Top

Journal of Cancer Research and Clinical Oncology

Published in:

01-06-2017 | Review – Clinical Oncology

The effects of microRNAs on glucocorticoid responsiveness

Authors: Huimin Wang, Xuxu Gou, Tang Jiang, Juan Ouyang

Published in: Journal of Cancer Research and Clinical Oncology | Issue 6/2017

Abstract

Purpose

Glucocorticoids (GCs) are of wide usage in the clinical treatment of lymphoblastic malignancies such as acute lymphoblastic leukemia. However, individually distinctive responsiveness to the GC therapy may attenuate their clinical efficacy, and more reliable predictor for GC resistance is still eagerly needed. Recent studies indicate that microRNAs (miRNAs), which demonstrate regulatory functions targeting mRNAs during the post-transcription, involved in the regulation of GCs sensitivity through several mechanisms, especially adjusting the magnitude of GC receptors (GRs), which mediates the cellular effects of GCs and plays a pivotal role in GCs sensitivity, inspiring that special miRNAs pattern could serve as the biomarkers to predict GC sensitivity and bring forth potential strategies for overcoming drug resistance. In this review, we discuss related miRNAs and their diverse effects exerted on multifaceted complexity of GCs responsiveness for further exploiting the molecular mechanism of GC resistance and future construction of the molecular diagnostic method and reverse GC resistance.

Methods

We have reviewed and searched for eligible literature relating to the effects of microRNAs on GC responsiveness from systematic PubMed searches.

Results

GC response can be mediated by miRNAs through influence on GC signaling pathway, leading to diverse glucocorticoid responsiveness. Mutations in miRNA gene also influence GC response. As well, GCs regulate the function of several miRNAs, and suggesting a bidirectional influence among them.

Conclusions

It is possible and necessary that miRNAs serve as stable biomarkers and GC resistant patients would benefit from an effective and early screening test.

Baek D, Villen J, Shin C et al (2008) The impact of microRNAs on protein output. Nature 455:64–71CrossRefPubMedPubMedCentral

Calin GA, Ferracin M, Cimmino A et al (2005) A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 353:1793–1801CrossRefPubMed

Cheng C, Wang Q, You W et al (2014) MiRNAs as biomarkers of myocardial infarction: a meta-analysis. PLoS One 9:e88566CrossRefPubMedPubMedCentral

Chriguer RS, Elias LL, da Silva IM Jr et al (2005) Glucocorticoid sensitivity in young healthy individuals: in vitro and in vivo studies. J Clin Endocrinol Metab 90:5978–5984CrossRefPubMed

Coskun E, von der Heide EK, Schlee C et al (2011) The role of microRNA-196a and microRNA-196b as ERG regulators in acute myeloid leukemia and acute T-lymphoblastic leukemia. Leuk Res 35:208–213CrossRefPubMed

Daufeldt S, Lanz R, Allera A (2003) Membrane-initiated steroid signaling (MISS): genomic steroid action starts at the plasma membrane. J Steroid Biochem Mol Biol 85:9–23CrossRefPubMed

de Kloet ER, Fitzsimons CP, Datson NA et al (2009) Glucocorticoid signaling and stress-related limbic susceptibility pathway: about receptors, transcription machinery and microRNA. Brain Res 1293:129–141CrossRefPubMed

Diederichs S, Haber DA (2006) Sequence variations of microRNAs in human cancer: alterations in predicted secondary structure do not affect processing. Cancer Res 66:6097–6104CrossRefPubMed

Gross KL, Oakley RH, Scoltock AB et al (2011) Glucocorticoid receptor alpha isoform-selective regulation of antiapoptotic genes in osteosarcoma cells: a new mechanism for glucocorticoid resistance. Mol Endocrinol 25:1087–1099CrossRefPubMedPubMedCentral

Han BW, Feng DD, Li ZG et al (2011) A set of miRNAs that involve in the pathways of drug resistance and leukemic stem-cell differentiation is associated with the risk of relapse and glucocorticoid response in childhood ALL. Hum Mol Genet 20:4903–4915CrossRefPubMedPubMedCentral

Harada M, Pokrovskaja-Tamm K, Soderhall S et al (2012) Involvement of miR17 pathway in glucocorticoid-induced cell death in pediatric acute lymphoblastic leukemia. Leuk Lymphoma 53:2041–2050CrossRefPubMed

Hung J-J (2013) Enhancement of miR-182 expression by Sp1 promotes lung cancer cell progression. FASEB J 27: 550.513

Jung SH, Wang Y, Kim T et al (2015) Molecular mechanisms of repeated social defeat-induced glucocorticoid resistance: role of microRNA. Brain Behav Immun 44:195–206CrossRefPubMed

Kapatai G, Nyangoma SO, Kearns P (2009) A study of aberrant DNA methylation in refractory and relapsed childhood acute lymphoblastic leukaemia. Blood 114:3456–3456

Kawashima H, Numakawa T, Kumamaru E et al (2010) Glucocorticoid attenuates brain-derived neurotrophic factor-dependent upregulation of glutamate receptors via the suppression of microRNA-132 expression. Neuroscience 165:1301–1311CrossRefPubMed

Kay P, Schlossmacher G, Matthews L et al (2011) Loss of glucocorticoid receptor expression by DNA methylation prevents glucocorticoid induced apoptosis in human small cell lung cancer cells. PLoS One 6:e24839CrossRefPubMedPubMedCentral

Kim J, Jeong D, Nam J et al (2015) MicroRNA-124 regulates glucocorticoid sensitivity by targeting phosphodiesterase 4B in diffuse large B cell lymphoma. Gene 558:173–180CrossRefPubMed

Kotani A, Ha D, Hsieh J et al (2009) miR-128b is a potent glucocorticoid sensitizer in MLL-AF4 acute lymphocytic leukemia cells and exerts cooperative effects with miR-221. Blood 114:4169–4178CrossRefPubMedPubMedCentral

Kotani A, Ha D, Schotte D et al (2010) A novel mutation in the miR-128b gene reduces miRNA processing and leads to glucocorticoid resistance of MLL-AF4 acute lymphocytic leukemia cells. Cell Cycle 9:1037–1042CrossRefPubMedPubMedCentral

Ledderose C, Mohnle P, Limbeck E et al (2012) Corticosteroid resistance in sepsis is influenced by microRNA-124-induced downregulation of glucocorticoid receptor-alpha. Crit Care Med 40:2745–2753CrossRefPubMed

Lin KT, Yeh YM, Chuang CM et al (2015) Glucocorticoids mediate induction of microRNA-708 to suppress ovarian cancer metastasis through targeting Rap1B. Nat Commun 6:5917CrossRefPubMedPubMedCentral

Llave C, Xie Z, Kasschau KD et al (2002) Cleavage of Scarecrow-like mRNA targets directed by a class of Arabidopsis miRNA. Science 297:2053–2056CrossRefPubMed

Lv M, Zhang X, Jia H et al (2012) An oncogenic role of miR-142-3p in human T-cell acute lymphoblastic leukemia (T-ALL) by targeting glucocorticoid receptor-alpha and cAMP/PKA pathways. Leukemia 26:769–777CrossRefPubMed

Matysiak M, Makosa B, Walczak A et al (2008) Patients with multiple sclerosis resisted to glucocorticoid therapy: abnormal expression of heat-shock protein 90 in glucocorticoid receptor complex. Mult Scler 14:919–926CrossRefPubMed

Miska EA, Alvarez-Saavedra E, Townsend M et al (2004) Microarray analysis of microRNA expression in the developing mammalian brain. Genome Biol 5:R68CrossRefPubMedPubMedCentral

Molitoris JK, McColl KS, Distelhorst CW (2011) Glucocorticoid-mediated repression of the oncogenic microRNA cluster miR-17 ~92 contributes to the induction of Bim and initiation of apoptosis. Mol Endocrinol 25:409–420CrossRefPubMedPubMedCentral

Moricke A, Zimmermann M, Reiter A et al (2010) Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia 24:265–284CrossRefPubMed

Murray MY, Rushworth SA, Zaitseva L et al (2013) Attenuation of dexamethasone-induced cell death in multiple myeloma is mediated by miR-125b expression. Cell Cycle 12:2144–2153CrossRefPubMedPubMedCentral

Nojima M, Maruyama R, Yasui H et al (2009) Genomic screening for genes silenced by DNA methylation revealed an association between RASD1 inactivation and dexamethasone resistance in multiple myeloma. Clin Cancer Res 15:4356–4364CrossRefPubMed

Ouyang J, Chen P, Jiang T et al (2012) Nuclear HSP90 regulates the glucocorticoid responsiveness of PBMCs in patients with idiopathic nephrotic syndrome. Int Immunopharmacol 14:334–340CrossRefPubMed

Ovcharenko D, Stolzel F, Poitz D et al (2011) miR-10a overexpression is associated with NPM1 mutations and MDM4 downregulation in intermediate-risk acute myeloid leukemia. Exp Hematol 39:1030–1042 (e1037) CrossRefPubMed

Rainer J, Ploner C, Jesacher S et al (2009) Glucocorticoid-regulated microRNAs and mirtrons in acute lymphoblastic leukemia. Leukemia 23:746–752CrossRefPubMed

Ramamoorthy S, Cidlowski JA (2013) Ligand-induced repression of the glucocorticoid receptor gene is mediated by an NCoR1 repression complex formed by long-range chromatin interactions with intragenic glucocorticoid response elements. Mol Cell Biol 33:1711–1722CrossRefPubMedPubMedCentral

Riester A, Issler O, Spyroglou A et al (2012) ACTH-dependent regulation of microRNA as endogenous modulators of glucocorticoid receptor expression in the adrenal gland. Endocrinology 153:212–222CrossRefPubMed

Roberts ML, Kino T, Nicolaides NC et al (2013) A novel point mutation in the DNA-binding domain (DBD) of the human glucocorticoid receptor causes primary generalized glucocorticoid resistance by disrupting the hydrophobic structure of its DBD. J Clin Endocrinol Metab 98:E790–E795CrossRefPubMedPubMedCentral

Rosati J, Spallotta F, Vincenti S et al (2008) Abstract 3832: Mir429 Regulates NO-dependent Differentiation Of Mouse Embryonic Stem Cells. Circulation 118:S_493

Schmidt S, Rainer J, Ploner C et al (2004) Glucocorticoid-induced apoptosis and glucocorticoid resistance: molecular mechanisms and clinical relevance. Cell Death Differ 11(Suppl 1):S45–S55CrossRefPubMed

Schratt GM, Tuebing F, Nigh EA et al (2006) A brain-specific microRNA regulates dendritic spine development. Nature 439:283–289CrossRefPubMed

Sifakis EG, Lambrou GI, Prentza A et al (2011) Elucidating the identity of resistance mechanisms to prednisolone exposure in acute lymphoblastic leukemia cells through transcriptomic analysis: a computational approach. J Clin Bioinforma 1:36CrossRefPubMedPubMedCentral

Smith LK, Tandon A, Shah RR et al (2013) Deep sequencing identification of novel glucocorticoid-responsive miRNAs in apoptotic primary lymphocytes. PLoS One 8:e78316CrossRefPubMedPubMedCentral

Sousa AR, Lane SJ, Cidlowski JA et al (2000) Glucocorticoid resistance in asthma is associated with elevated in vivo expression of the glucocorticoid receptor beta-isoform. J Allergy Clin Immunol 105:943–950CrossRefPubMed

Surjit M, Ganti KP, Mukherji A et al (2011) Widespread negative response elements mediate direct repression by agonist-liganded glucocorticoid receptor. Cell 145:224–241CrossRefPubMed

Syring I, Bartels J, Holdenrieder S et al (2015) Circulating serum miRNA (miR-367-3p, miR-371a-3p, miR-372-3p and miR-373-3p) as biomarkers in patients with testicular germ cell cancer. J Urol 193:331–337CrossRefPubMed

Tessel MA, Benham AL, Krett NL et al (2011) Role for microRNAs in regulating glucocorticoid response and resistance in multiple myeloma. Horm Cancer 2:182–189CrossRefPubMedPubMedCentral

Uchida S, Nishida A, Hara K et al (2008) Characterization of the vulnerability to repeated stress in Fischer 344 rats: possible involvement of microRNA-mediated down-regulation of the glucocorticoid receptor. Eur J Neurosci 27:2250–2261CrossRefPubMed

Vreugdenhil E, Verissimo CS, Mariman R et al (2009) MicroRNA 18 and 124a down-regulate the glucocorticoid receptor: implications for glucocorticoid responsiveness in the brain. Endocrinology 150:2220–2228CrossRefPubMed

Wang X, Li C, Ju S et al (2011) Myeloma cell adhesion to bone marrow stromal cells confers drug resistance by microRNA-21 up-regulation. Leuk Lymphoma 52:1991–1998CrossRefPubMed

Wang LQ, Kwong YL, Wong KF et al (2014) Epigenetic inactivation of mir-34b/c in addition to mir-34a and DAPK1 in chronic lymphocytic leukemia. J Transl Med 12:52CrossRefPubMedPubMedCentral

Wu M, Jolicoeur N, Li Z et al (2008) Genetic variations of microRNAs in human cancer and their effects on the expression of miRNAs. Carcinogenesis 29:1710–1716CrossRefPubMed

Wu CT, Chiou CY, Chiu HC et al (2013) Fine-tuning of microRNA-mediated repression of mRNA by splicing-regulated and highly repressive microRNA recognition element. BMC Genomics 14:438CrossRefPubMedPubMedCentral

Xu J, Li CX, Li YS et al (2011) MiRNA-miRNA synergistic network: construction via co-regulating functional modules and disease miRNA topological features. Nucleic Acids Res 39:825–836CrossRefPubMed

Yang A, Ma J, Wu M et al (2012) Aberrant microRNA-182 expression is associated with glucocorticoid resistance in lymphoblastic malignancies. Leuk Lymphoma 53:2465–2473CrossRefPubMed

Zhang L, Hou D, Chen X et al (2012) Exogenous plant MIR168a specifically targets mammalian LDLRAP1: evidence of cross-kingdom regulation by microRNA. Cell Res 22:107–126CrossRefPubMed

Zheng Y, Xiong S, Jiang P et al (2012) Glucocorticoids inhibit lipopolysaccharide-mediated inflammatory response by downregulating microRNA-155: a novel anti-inflammation mechanism. Free Radic Biol Med 52:1307–1317CrossRefPubMed

Zou YF, Xu JH, Wang F et al (2013) Association study of glucocorticoid receptor genetic polymorphisms with efficacy of glucocorticoids in systemic lupus erythematosus: a prospective cohort study. Autoimmunity 46:531–536CrossRefPubMed

Title: The effects of microRNAs on glucocorticoid responsiveness
Authors: Huimin Wang
Xuxu Gou
Tang Jiang
Juan Ouyang
Publication date: 01-06-2017
Publisher: Springer Berlin Heidelberg
Published in: Journal of Cancer Research and Clinical Oncology / Issue 6/2017
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-017-2388-4

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 6/2017

Genetic and epigenetic patterns in patients with the head-and-neck paragangliomas associate with differential clinical characteristics

Influence of CYP2C19*2/*17 genotype on adverse drug reactions of voriconazole in patients after allo-HSCT: a four-case report

Long non-coding RNA UCA1 regulates the expression of Snail2 by miR-203 to promote hepatocellular carcinoma progression

Variables associated with patient-reported outcomes in persons with chronic myeloid leukemia receiving tyrosine kinase-inhibitor therapy

Exosomes-mediated transfer of long noncoding RNA ZFAS1 promotes gastric cancer progression

Dermatux: phase IV trial of Cetuximab plus FOLFIRI in first-line metastatic colorectal cancer receiving a pre-defined skin care

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials

Influence of CYP2C192/17 genotype on adverse drug reactions of voriconazole in patients after allo-HSCT: a four-case report